Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Conjunctival and Scleral Avascular Lesions
NCT05476042Phase 3Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of erythropoietin in scleral necrosis (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: The size of the conjunctival epithelial defect at 1 week. Status: unknown.
02
Drugs
erythropoietin
03
Conditions
scleral necrosis
Beyond the preview
Go deeper on NCT05476042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476042.